Supplementation with <i>Lactobacillus kefiranofaciens</i> ZW3 from Tibetan Kefir improves depression-like behavior in stressed mice by modulating the gut microbiota

Sun, Ye; Geng, Weitao; Pan, Yajing; Wang, Jinju; Xiao, Ping; Wang, Yanping

doi:10.1039/c8fo02096e

Cited by 72 publications

(50 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be possible that the antibacterial effects of this exopolysaccharide extend to other species in the gut microbiota. This supports the finding that L. kefiranofaciens supplementation ameliorated depressive-like behaviors in chronic-stressed mice by regulating gut microbiota content, which included the decreased abundance of Proteobacteria, a phylum that includes pathogens such as Salmonella (Sun et al, 2019). Other mice studies also supported the role of L. kefiranofaciens in modulating gut microbiota composition (Jeong et al, 2017b;Xing et al, 2018).…”

Section: Exopolysaccharide Peripheral Inflammation and Gut Microbiotasupporting

confidence: 79%

“…These treated mice also showed several physiological alterations. Levels of circulating TRP, splenic IL-10 and beneficial gut bacteria (e.g., Lachnospiraceae, Bifidobacteriaceae, and Akkermansia) increased, and KYN/TRP ratio, splenic IL-6 and IFN-γ levels and Proteobacteria abundance decreased (Sun et al, 2019). What factors mediate such broad effects of L. kefiranofaciens on the TRP/KYN pathway, immune system, HPA axis and gut microbiota remain unclear, but exopolysaccharide is potentially a candidate (Figure 2D).…”

Section: Lactobacillus Kefiranofaciensmentioning

confidence: 99%

“…The only known metabolite of L. kefiranofaciens is an exopolysaccharide called kefiran (Maeda et al, 2004;Xing et al, 2017). The intake of kefiran modulated the gut mucosal immune system of mice (Vinderola et al, 2006), which could potentially account for changes in splenic cytokines seen in depressed mice (Sun et al, 2019). Kefiran was also shown to protect human enterocyte cell lines from adhesion and damage inflicted by toxins of pathogenic bacteria (Santos et al, 2003;Medrano et al, 2008).…”

Section: Exopolysaccharide Peripheral Inflammation and Gut Microbiotamentioning

confidence: 99%

“…For instance, heat-killed L. paracasei benefited the human and animal host, in terms of neurochemical and behavioral changes (Corpuz et al, 2018;Murata et al, 2018;Wei et al, 2019). Some probiotics, such as L. reuteri, L. paracasei, L. plantarum, L. gasseri, L. kefiranofaciens, B. breve, and B. infantis, promoted the colonization of other beneficial microbes that contributed to the reduction of depressive-like symptoms in animals (Marin et al, 2017;Dhaliwal et al, 2018;Jang et al, 2019;Sun et al, 2019;Tian et al, 2019;Wei et al, 2019).…”

Section: Heterogeneity Of Gut Microbiota Compositionmentioning

confidence: 99%

“…Probiotics that have been shown to improve the outcome of this test include L. helveticus (Liang et al, 2015), L. plantarum (Liu Y.W. et al, 2016), L. paracasei (Wei et al, 2019), L. kefiranofaciens (Sun et al, 2019), B. infantis (Tian et al, 2019), and B. breve (Tian et al, 2019). Among these probiotics, L. plantarum (Liu Y.W.…”

Section: Heterogeneity Of Depressionmentioning

confidence: 99%

See 4 more Smart Citations

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

et al. 2020

View full text Add to dashboard Cite

The accumulating knowledge of the host-microbiota interplay gives rise to the microbiota-gut-brain (MGB) axis. The MGB axis depicts the interkingdom communication between the gut microbiota and the brain. This communication process involves the endocrine, immune and neurotransmitters systems. Dysfunction of these systems, along with the presence of gut dysbiosis, have been detected among clinically depressed patients. This implicates the involvement of a maladaptive MGB axis in the pathophysiology of depression. Depression refers to symptoms that characterize major depressive disorder (MDD), a mood disorder with a disease burden that rivals that of heart diseases. The use of probiotics to treat depression has gained attention in recent years, as evidenced by increasing numbers of animal and human studies that have supported the antidepressive efficacy of probiotics. Physiological changes observed in these studies allow for the elucidation of probiotics antidepressive mechanisms, which ultimately aim to restore proper functioning of the MGB axis. However, the understanding of mechanisms does not yet complete the endeavor in applying probiotics to treat MDD. Other challenges remain which include the heterogeneous nature of both the gut microbiota composition and depressive symptoms in the clinical setting. Nevertheless, probiotics offer some advantages over standard pharmaceutical antidepressants, in terms of residual symptoms, side effects and stigma involved. This review outlines antidepressive mechanisms of probiotics based on the currently available literature and discusses therapeutic potentials of probiotics for depression.

show abstract

Section: Exopolysaccharide Peripheral Inflammation and Gut Microbiotasupporting

confidence: 79%

Section: Lactobacillus Kefiranofaciensmentioning

confidence: 99%

Section: Exopolysaccharide Peripheral Inflammation and Gut Microbiotamentioning

confidence: 99%

Section: Heterogeneity Of Gut Microbiota Compositionmentioning

confidence: 99%

Section: Heterogeneity Of Depressionmentioning

confidence: 99%

See 3 more Smart Citations

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

et al. 2020

View full text Add to dashboard Cite

show abstract

Microbiome Engineering for Metabolic Disorders

Aggarwal

Koh

Srivastava

et al. 2022

Principles in Microbiome Engineering

View full text Add to dashboard Cite

Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community

Geng

Yang

et al. 2022

J Sci Food Agric

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is becoming the most common progressive liver diseases. Therapeutic strategy based on gut-liver axis and probiotics is a promising approach for the treatment of NAFLD. However, rare probiotics have been applied in NAFLD treatment, and the involved molecular mechanism is not entirely clear.RESULTS: We initially identified a novel functional probiotic, Lactobacillus kefiranofaciens ZW3, on the lipid deposition by a simple and rapid zebrafish model. Supplementation with ZW3 to the methionine and choline deficient (MCD) diet induced NAFLD rats could improve the liver impairments and reduce inflammation through TLR4-MyD88 and JNK signaling pathways. Moreover, ZW3 modulated gut microbiota by promoting relative abundance of Firmicutes and Lactobacillus, decreasing the abundance of Escherichia-Shigella and Bacteroides. Functional prediction of microbiome showed ZW3 presented potential enhancement on carbohydrate and lipid metabolism, cell process control and signal transduction processes, and reduced several human diseases.CONCLUSION: This present study identified a novel probiotic and its protective effects on NAFLD, and interpreted the interactions of ZW3 with the immune system and gut microbiota involved in gut-liver axis.

show abstract

Supplementation with Lactobacillus kefiranofaciens ZW3 from Tibetan Kefir improves depression-like behavior in stressed mice by modulating the gut microbiota

Abstract: ZW3 regulated the biomarkers and behaviors associated with tryptophan metabolism, the HPA axis, and the immune system in depressed mice by regulating the gut microbiota.

Cited by 72 publications

References 55 publications

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential

Microbiome Engineering for Metabolic Disorders

Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community

Contact Info

Product

Resources

About